FNY Investment Advisers LLC Sells 26,900 Shares of Humana Inc. (NYSE:HUM)

FNY Investment Advisers LLC cut its holdings in Humana Inc. (NYSE:HUM - Free Report) by 98.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 360 shares of the insurance provider's stock after selling 26,900 shares during the quarter. FNY Investment Advisers LLC's holdings in Humana were worth $95,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. FPC Investment Advisory Inc. purchased a new stake in Humana in the fourth quarter worth about $27,000. Centricity Wealth Management LLC bought a new stake in shares of Humana in the 4th quarter worth approximately $30,000. LFA Lugano Financial Advisors SA grew its stake in shares of Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after buying an additional 45 shares during the last quarter. OFI Invest Asset Management bought a new position in Humana during the 4th quarter valued at approximately $33,000. Finally, Riverview Trust Co purchased a new position in Humana during the first quarter valued at $34,000. 92.38% of the stock is currently owned by institutional investors.

Humana Trading Up 0.1%

Humana stock opened at $235.58 on Tuesday. Humana Inc. has a 52-week low of $212.45 and a 52-week high of $406.46. The company has a market cap of $28.43 billion, a P/E ratio of 23.68, a P/E/G ratio of 2.05 and a beta of 0.43. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The business has a 50-day simple moving average of $249.53 and a two-hundred day simple moving average of $261.98.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The firm's revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the firm posted $7.23 earnings per share. Analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.50%. The ex-dividend date of this dividend is Friday, June 27th. Humana's dividend payout ratio is presently 25.04%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on HUM shares. Cantor Fitzgerald reissued a "neutral" rating and issued a $290.00 target price on shares of Humana in a research note on Thursday, May 1st. Oppenheimer raised their price objective on shares of Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research note on Thursday, May 1st. JPMorgan Chase & Co. decreased their target price on shares of Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Raymond James upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target on the stock in a report on Thursday, May 1st. Finally, Barclays set a $268.00 price objective on shares of Humana and gave the stock an "equal weight" rating in a report on Thursday, June 12th. Seventeen equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Humana presently has an average rating of "Hold" and an average price target of $284.24.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.